Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy - PubMed
5 hours ago
- #immunotherapy
- #PDAC
- #nanoparticle
- Losartan preconditioning transforms the high-stiffness tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) into a more compliant state, enhancing drug delivery.
- A hybrid nanoparticle (IGEL), co-encapsulating gemcitabine and IL-12 circular RNA, is delivered more effectively after losartan pretreatment.
- Losartan pretreatment improves vascular perfusion, nanoparticle penetration, and reprograms the tumor immune microenvironment, leading to suppressed tumor growth and prolonged survival.
- Multimodal imaging and transcriptomic profiling confirm deeper intratumoral accumulation of IGEL and stromal/immune microenvironment remodeling post-losartan.
- The study supports losartan-primed IGEL as a promising therapeutic strategy for PDAC, overcoming physical and immunologic barriers.